Publications by authors named "Maika Klaiber-Hakimi"
Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma in the GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT03617731) resulted in a significant increase of minimal residual disease negativity (MRD-) rates after induction therapy. A total of 662 patients were randomly assigned to receive induction therapy with Isa-RVd (n = 331) or RVd (n = 329), followed by single or tandem autologous stem-cell transplant and second random assignment to maintenance with lenalidomide alone or Isa-lenalidomide.
View Article and Find Full Text PDFArticle Synopsis
- A new coronavirus disease called SARS-CoV-2 emerged in 2019, leading to an ongoing pandemic with variable symptoms and complications affecting blood cell production and clotting.
- Four COVID-19 vaccines were released in 2020, but some were linked to hematological issues like vaccine-induced immune thrombotic thrombocytopenia (VITT) and immune thrombocytopenic purpura (ITP).
- This case report discusses two patients who developed ITP after receiving the AstraZeneca vaccine, showing a positive response to treatment with thrombopoietin-receptor agonists, highlighting the need for clearer treatment guidelines for vaccination-related blood disorders.
Background: Anti-CD38 monoclonal antibodies have consistently shown increased efficacy when added to standard of care for patients with multiple myeloma. We aimed to assess the efficacy of isatuximab in addition to lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed transplantation-eligible multiple myeloma.
Methods: This open-label, multicentre, randomised, active-controlled, phase 3 trial was done at 67 academic and oncology practice centres in Germany.